Veniti

Veniti is the private company founded in 2010 which developed and implemented the VICI VENOUS STENT system for treatment of occlusal diseases of veins. The headquarters of the company is located in the American Fremonte, the State of California.

History

2018: Boston Scientific purchased Veniti

On August 8, 2018 the producer of the medical equipment Boston Scientific announced acquisition of Veniti company which investor it was since 2016. By the time of the announcement of the transaction of Boston Scientific owned 25% of stocks of the company and should pay $108 million more for acquisition of other share block and $52 million for registration of the VICI stent for sale.

The self-extending stent from a nitinol of VICI was specially developed taking into account anatomy of veins – it should resist to compression and save passability and flexibility during all life of the patient. The VICI stent received the certificate of CE in 2013, and in June, 2018 Veniti submitted the application for approbation of a product to the USA before sales, using results of recently completed reference research VIRTUS. Though occlusal diseases of veins affect more than 1.1 million patients in the USA and Western Europe annually, in the USA the stents held for use in a peripheral venous system are not used yet, and VICI can become the first similar device.

Boston Scientific purchased the producer of special venous Veniti stents

The senior vice president and the head of division of peripheral surgeries of Boston Scientific Jeff Mirviss notes that purchase of Veniti will become profitable acquisition for Boston Scientific expanding a packet of the equipment for peripheral venous interventions, and the VICI stent will rise in one row with the leading Boston Scientific platform for AngioJet trombektomiya. It is expected that purchase costs of Veniti will easily pay off in 2018 and 2019, and afterwards the company will make net profit.

By August, 2018 the VICI stent is the research device and is still unavailable to sale.^[1]

Notes